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Abstract In rat-1 fibroblasts stably expressing K1d-adrenocep-
tors BMY 7378, phentolamine, chloroethylclonidine and 5-
methyl urapidil decreased basal [Ca2+]i. WB 4101 induced a
very small effect on this parameter but when added before the
other antagonists it blocked their effect. All these agents
inhibited the action of norepinephrine. Phorbol myristate acetate
also blocked the effect of norepinephrine and decreased basal
[Ca2+]i. Staurosporine inhibited these effects of the phorbol
ester. Our results suggest that: (1) K1d-adrenoceptors exhibit
spontaneous ligand-independent activity, (2) BMY 7378, phen-
tolamine, chloroethylclonidine and 5-methyl urapidil act as
inverse agonists and (3) protein kinase C activation blocks
spontaneous and agonist-stimulated K1d-adrenoceptor activity.
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1. Introduction
K1-Adrenoceptors are members of the G-protein-coupled
family of receptors, which mediate some of the physiological
actions of the natural catecholamines, epinephrine and nor-
epinephrine. Three K1-adrenoceptor subtypes have been
cloned and they are referred to as K1a-, K1b- and K1d-adreno-
ceptors, as recommended by the International Union of Phar-
macology Committee for Receptor Nomenclature and Drug
Classi¢cation [1]. These receptors are coupled to phosphoino-
sitide turnover/calcium mobilization and, depending on the
cell type, to other signaling devices [2,3].
It has been generally assumed that receptors are activated
by agonists and that antagonists bind to the receptors without
altering their activity but rather blocking the action of ago-
nists. However, recent studies indicate that some receptors
have spontaneous basal activity in the absence of any ligand,
i.e. they can modulate downstream e¡ector elements and in-
duce functional responses without agonists [4^6]. In fact, it
has been observed that some agents not only block the action
of agonists but also suppress agonist-independent receptor
activity; these agents are generally referred to as inverse ago-
nists [4^6].
During our studies with rat-1 ¢broblasts expressing the K1-
adrenoceptor subtypes, we observed that chloroethylclonidine
behaved as a partial agonist for the K1a subtype and antago-
nized the e¡ect of norepinephrine in ¢broblasts expressing
either of the other two subtypes [7]. Interestingly, we consis-
tently observed that chloroethylclonidine decreases the basal
concentration of intracellular calcium ([Ca2]i) in ¢broblasts
expressing the K1d subtype [7]. We were puzzled by this ¢nd-
ing and further investigated it. Our data show that other
adrenergic antagonists induce this e¡ect, suggesting that it is
due to inverse agonism on agonist-independent activity of
K1d-adrenoceptors; in addition, it was observed that such en-
dogenous activity can also be blocked by activation of protein
kinase C.
2. Materials and methods
(3)Norepinephrine, endothelin-1, phorbol 12-myristate 13-acetate
(PMA), staurosporine and bovine serum albumin were obtained
from Sigma Chemical Co. Fura 2/AM was from Molecular Probes.
Chloroethylclonidine, WB 4101, BMY 7378 and 5-methyl urapidil
were from Research Biochemicals International. Phentolamine was a
generous gift from Ciba-Geigy. Dulbecco’s mod¢ed Eagle’s medium
(DMEM), fetal bovine serum, trypsin, antibiotics and other reagents
used for cell culture were from Gibco BRL.
Rat-1 ¢broblasts stably expressing K1d-adrenoceptors (cloned from
rat brain [8]) were kindly provided to us by Drs. L. Allen, R.J. Lef-
kowitz and M.G. Caron (Duke University, Durham, NC, USA).
Transfected cells were grown as described [9] in glutamine-containing
high glucose DMEM supplemented with 10% fetal bovine serum,
100 Wg/ml streptomycin, 100 U/ml penicillin and 0.25 Wg/ml ampho-
tericin B, at 37‡C under a 5% CO2 atmosphere. For selection, cells
were cultured in the presence of the neomycin analogue, G418 sulfate
(300 Wg/ml).
Con£uent cells were incubated overnight in G418-free DMEM
without serum. Cells were loaded with 5 WM Fura 2/AM at 37‡C
for 1 h, then washed with Krebs-Ringer-HEPES bu¡er containing
0.05% bovine serum albumin, pH 7.4, detached from the plates with
trypsin and washed three times, to remove unincorporated dye. Cells
were resuspended in the same bu¡er, at a concentration of approx-
imately 106 cells/ml. Fluorescence measurements were performed with
excitation monochromators set at 340 and 380 nm, with a chopper
interval of 0.5 s, and the emission monochromator set at 510 nm. The
[Ca2]i was calculated according to Grynkiewicz et al. [10] using the
software provided by AMINCO-Bowman; traces were directly ex-
ported to the graphs.
3. Results
Representative traces of the e¡ects of norepinephrine and
the selective K1d-adrenergic antagonist BMY 7378 [11] on
[Ca2]i are presented in Fig. 1. It can be observed that nor-
epinephrine induced an almost immediate increase of [Ca2]i ;
the increase was 2^3-fold the basal level in agreement with
previous data [9]. As expected, BMY 7378 inhibited this ac-
tion of norepinephrine in a concentration-dependent fashion,
as evidenced by a gradual decrease in the magnitude of the
response and the velocity of the increase (Fig. 1). Interest-
ingly, BMY 7378 by itself decreased, also in a concentra-
tion-dependent fashion, the basal level of [Ca2]i. The de-
crease was relatively small (30^50 nM) but it was consistent
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and clearly evidenced by the gradual response in magnitude
and speed (slope) (Fig. 1). In cells treated with 10 WM BMY
7378 there was a clear decrease in basal [Ca2]i and the e¡ect
of norepinephrine was almost abolished; however, the peptide
mediator endothelin-1 induced a full response indicating that
the action of BMY 7378 was not due to a general deleterious
action on the cells but rather to a selective e¡ect on the K1d-
adrenoceptors.
It can be observed that the antagonists WB 4101, 5-methyl
urapidil, phentolamine, BMY 7378 and chloroethylclonidine
inhibited in a concentration-dependent fashion the e¡ect of
norepinephrine on [Ca2]i (Fig. 2, upper left panel). Chloro-
ethylclonidine only partially inhibited the e¡ect of the cate-
cholamine, even at the highest concentration tested (100 WM).
The e¡ect of the di¡erent antagonists on basal [Ca2]i was
studied. WB 4101 modi¢ed basal [Ca2]i to a very small extent
(0^10 nM), whereas the other agents tested induced concen-
tration-dependent decreases of basal [Ca2]i of 30^50 nM;
5-methyl urapidil consistently was less e¡ective than phentol-
amine, BMY 7378 or chloroethylclonidine (Fig. 2).
We took advantage of the very small ‘inverse e⁄cacy’
of WB 4101 and tested whether it could block the action of
the other agents. As shown in Fig. 3, the previous addition of
WB 4101 clearly blocked the e¡ect of 5-methyl urapidil, phen-
tolamine, BMY 7378 and chloroethylclonidine on basal
[Ca2]i.
Activation of protein kinase C with phorbol esters blocked
K1-adrenergic action [12,13], an e¡ect associated with adreno-
ceptor phosphorylation [14^18]. Marked di¡erences in sensi-
tivity to the inhibitory action of protein kinase C activation
have been observed among the receptor subtypes, K1d-adreno-
ceptors being particularly sensitive [9]. We tested whether
PMA was able to alter [Ca2]i. As can be observed in Fig.
4, PMA decreased basal [Ca2]i in a concentration-dependent
fashion; the decrease was of similar magnitude as that in-
duced by the adrenergic antagonists tested. As expected,
when the cells were treated with PMA the e¡ect of norepi-
nephrine was blocked but not that of endothelin-1 (Fig. 4).
Staurosporine, an inhibitor of protein kinase C, blocked the
e¡ects of PMA on both basal [Ca2]i and the action of nor-
epinephrine (Fig. 4). Similar action was observed with other
inhibitors (data not shown).
4. Discussion
Our present data indicate that K1d-adrenoceptors expressed
in rat-1 ¢broblasts exhibit spontaneous ligand-independent
activity. Some agents such as 5-methyl urapidil, phentolamine,
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Fig. 1. E¡ect of adrenergic agents on intracellular calcium concentration ([Ca2]i). Rat-1 ¢broblasts expressing K1d-adrenoceptors were incu-
bated with 10 WM norepinephrine (NE) and the indicated concentrations of BMY 7378 (BMY). In the last trace the e¡ect of 10 nM endothe-
lin-1 (ET) is shown. Traces are representative of 4^6 experiments using di¡erent cell preparations.
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BMY 7378 or chloroethylclonidine can block such activity,
i.e. they seem to be acting as inverse agonists. This notion is
supported by the fact that WB 4101, which is essentially de-
void of such activity, can block the action of the inverse
agonists as well as the e¡ect of the agonist norepinephrine.
We observed some di¡erences in the potency order for in-
hibiting the norepinephrine response as compared to that for
decreasing basal [Ca2]i. Such di¡erences may be due to the
fact that inverse agonism re£ects not only drug a⁄nity but
also the ability of the ligand to stabilize the receptor in an
inactive conformation. Di¡erences may exist in inverse intrin-
sic activities that could modify the dose-response relationship,
not only in e⁄cacy but also in apparent potency, if receptor
reserve exits.
The data obtained with PMA are consistent with this. Ac-
tivation of protein kinase C by this phorbol ester blocks the
increase in [Ca2]i induced by norepinephrine as well as the
spontaneous agonist-independent receptor activity. The data
suggest that the protein kinase C-mediated phosphorylation
‘freezes’ the K1d-adrenoceptor in an inactive conformation.
The fact that staurosporine blocks the decrease in [Ca2]i
induced by PMA and also the ability of the active phorbol
ester to inhibit the action of norepinephrine suggests that both
events are likely mediated through the same process, i.e. re-
ceptor phosphorylation, mediated through protein kinase C
activation.
The mechanism through which the spontaneously active
receptor modulates [Ca2]i is not known. It may involve
IP3-mediated liberation of calcium from intracellular pools
and/or modulation of calcium channels and extrusion mecha-
nisms. This issue is far from trivial, especially considering that
these ¢broblasts express a calcium sensor that is a G-protein-
coupled receptor [19]. In addition, it is likely that some adap-
tation mechanism(s) may be operating in these ¢broblasts
since the basal [Ca2]i is no di¡erent from that observed in
non-transfected cells or in cells transfected with the other
subtypes (data not shown).
It was previously observed that sustained treatment with
K1-adrenergic antagonists results in an up-regulation of K1b-
adrenoceptors in rat-1 ¢broblasts expressing a constitutively
active mutant but not the wild type receptor [20]. Interest-
ingly, in this study phentolamine and WB 4101 had similar
inverse activity [20]. Similarly it is interesting that chloroethyl-
clonidine behaves as an antagonist in cells expressing K1b-
adrenoceptors, as a partial agonist in cells expressing the
K1a subtype [7] and as an inverse agonist in ¢broblasts ex-
pressing K1d-adrenoceptors.
To the best of our knowledge this is the ¢rst demonstration
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Fig. 2. E¡ect of adrenergic antagonists on basal and norepinephrine-stimulated intracellular calcium concentration ([Ca2]i). Upper left panel:
Cells were incubated with the indicated concentrations of the di¡erent antagonists, 2 min later 10 WM norepinephrine was added. Data were
normalized to the e¡ect of 10 WM norepinephrine alone (1=100% of norepinephrine e¡ect). Other panels: The changes in the basal [Ca2]i ob-
served during the addition of the antagonists are presented. Basal [Ca2]i was 155 þ 15 nM. The antagonists used were: WB 4101 (open circles),
5-methyl urapidil (open squares, 5-MU), phentolamine (solid squares, PHENT), BMY 7378 (solid circles, BMY) and chloroethylclonidine (solid
diamonds, CEC). Plotted are the means and vertical lines represent the S.E.M. of 4^7 experiments using di¡erent cell preparations; when no
S.E.M. are shown they are within the symbol.
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Fig. 3. E¡ect of WB 4101 on the e¡ect of adrenergic antagonists on basal intracellular calcium concentration ([Ca2]i). Upper panel: The
changes due to the addition of 1 WM of the indicated agents are shown; where indicated WB 4101 was added alone or V2 min before other
agents and the total change in basal [Ca2]i, i.e. that due to WB 4101 plus the other agent, is indicated. 5-Methyl urapidil (5-MU), phentol-
amine (PHENT), BMY 7378 (BMY), chloroethylclonidine (CEC). Plotted are the means and vertical lines represent the S.E.M. of 3^4 experi-
ments using di¡erent cell preparations. Lower panels: Representative traces of the e¡ect of antagonists on calcium concentration; the e¡ect of
10 WM norepinephrine (NE) is also shown.
Fig. 4. E¡ect of PMA on basal intracellular calcium concentration ([Ca2]i). Left panel: E¡ect of di¡erent concentrations of PMA on basal
[Ca2]i ; plotted are the means and vertical lines represent the S.E.M. of 5^6 experiments using di¡erent cell preparations. Right panels: Repre-
sentative traces of the e¡ects of PMA and 1 WM staurosporine (STAU) on intracellular calcium concentration; the e¡ects of 10 WM norepi-
nephrine (NE) and 10 nM endothelin-1 (ET) are also shown.
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of inverse agonism in this adrenergic subtype. Considering the
important physiological (smooth muscle contraction) and
physiopathological roles that this K1d-adrenergic subtype
seems to play in hypertension [21^24], the possibility that in-
verse agonists could be therapeutically useful seems worth
considering.
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